Locations:
SearchAdvertisement
Combining dual inhibition with anti-PD1 therapy yielded >60% rate of complete tumor regression
A range of pituitary tumor-related conditions all benefit from a multidisciplinary approach
Cleveland Clinic researchers pursue answers on basic science and clinical fronts
Insights from 15 years of experience of Cleveland Clinic’s spine tumor board
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Study demonstrates its role in tumor lethality, raises prospect of therapeutic targets
We now have an expanded toolbox to extend survival and lessen treatment toxicity
Focused ultrasound is paired with ALA to utilize sonodynamic therapy to target cancer cells
Can T-cell immunophenotyping help inform treatment decisions?
Intracranial injection of supercharged immune cells proceeds to phase 2 testing
Insights into the choice between craniotomy and endoscopic endonasal approaches
Advertisement
Advertisement